Biotech Startups

Edity develops an AI-powered platform that engineers therapeutic proteins and uses immune cells (such as T-cells and NK cells) as carriers to deliver them to diseased tissues. Its plug-and-play technology is compatible with allogeneic approaches and aimed at creating new modalities for intracellular therapy.

4 investors

Electrochaea is a Power-to-Gas technology company whose patented biomethanation process uses a proprietary strain of archaea to convert CO2 and green hydrogen into grid-quality renewable e-methane. It licenses its technology to energy and industrial companies to produce low-carbon methane for gas grids and renewable fuel across multiple sectors.

4 investors

ElevateBio is a contract development and manufacturing organization (CDMO) for advanced therapies, offering discovery, process development, analytics, manufacturing, and regulatory support for cell therapies, viral vectors, mRNA therapeutics, and gene editing. It partners with drug developers to bring cell and gene therapies from early discovery through commercial-scale cGMP manufacturing.

4 investors

Elkedonia is a biotech company developing a novel antidepressant treatment that targets intracellular neuroplasticity pathways rather than synaptic mechanisms, with the goal of providing rapid, long-lasting relief for depression patients. The company aims to create an accessible therapy for all patients regardless of geography, age, or comorbidities, while avoiding dependence, sedation, or psychotic side effects.

4 investors

Scene Health (formerly emocha) runs a video Directly Observed Therapy (DOT) program that uses asynchronous video and a multilingual app, paired with a high-touch care team, to monitor and improve medication adherence for patients with chronic conditions. It serves health plans, public health departments, pharmaceutical sponsors, CROs, and clinical trial sites to improve clinical outcomes, reduce costs, and track real-time adherence data.

4 investors

Empirical Bio builds machine learning software that predicts and optimizes the structure of enzymes and other biomolecules. Biotech research teams use it to narrow down candidates computationally before moving to the bench, which reduces the number of laboratory testing cycles required.

4 investors

ENA Respiratory develops and brings respiratory treatments to market across the US and other regions. The company operates at the intersection of pharmaceutical product development and clinical innovation, with deep expertise in bringing early-stage respiratory therapies through development and regulatory approval.

4 investors

Enable Injections develops and manufactures enFuse, a wearable drug delivery device that delivers large volumes of pharmaceutical and biologic therapeutics subcutaneously for patients with chronic diseases. The company serves healthcare providers, payers, and patients by offering a mechanical hands-free alternative to intravenous treatment.

4 investors

Endomedix develops polysaccharide-based biomaterials and medical technology, with a pipeline moving from polysaccharide chemistry toward preclinical testing and clinical trials. The company works with a small internal R&D team supported by external scientific consultants.

4 investors

Endpoint Health develops and commercializes precision therapeutics and therapy-guiding diagnostic tests targeted to each patient's biology, focused on immune-driven critical and chronic illnesses.

4 investors

Enginzyme develops a technology platform for sustainable chemistry applications aimed at removing carbon dioxide from the atmosphere. The company offers products, services, and end-to-end support across the discovery and scale-up phases of sustainable chemistry solutions.

4 investors

Pekilo is a mycoprotein-based ingredient that provides digestible proteins and dietary fiber as a sustainable alternative to meat products. The product targets food manufacturers and nutritional supplement producers seeking sustainable protein sources.

4 investors

Enliven Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops small molecule therapeutics using a precision medicine approach, with a focus on oncology and hematology. Its discovery work combines clinically validated biological targets with differentiated chemistry to develop drugs for unmet medical needs.

4 investors

Enzyme offers a quality management system software and QA/RA consulting services to help life science companies obtain FDA approval and maintain ongoing regulatory compliance. It serves medical device and life science companies.

4 investors

EpilepsyGTx is a preclinical-stage biotech developing gene therapies for focal refractory epilepsy (FRE), with the aim of making patients seizure free.

4 investors

Epinoma develops EpiAmp, a methyl-preserving amplification technology to analyze epigenetic changes and methylation patterns for applications in disease detection, drug development, and patient stratification. The company serves research institutions, pharmaceutical companies, and clinical diagnostic organizations in the biotech and healthcare sectors.

4 investors

Erg Bio converts waste biomass into fermentable sugars and intermediates for synthetic aviation fuels and chemicals, using an advanced solvent process and a proprietary yeast that produces enzymes and ferments sugars. The technology is feedstock-agnostic and licensed from the DOE Joint BioEnergy Institute, targeting energy and chemical production markets.

4 investors

erthos develops regenerative biomaterials as alternatives to plastic, aiming to reduce plastic pollution while avoiding harmful compounds like PFAS found in some "green" products. The company positions its materials as safer, more sustainable options across consumer and packaging applications.

4 investors

Eternatear develops diagnostic and therapeutic products for dry eye disease, particularly targeting Meibomian Gland Dysfunction. The company is founded by experienced ophthalmology and medical device leaders with extensive track records in bringing dry eye treatments to market.

4 investors

Evox Therapeutics develops exosome-based gene editing therapies using its ExoEdit platform, which combines exosome delivery with a proprietary CRISPR-based editor to treat severe neurodegenerative and other genetically-driven diseases. The therapies target the central nervous system to address the root cause of neurodegeneration.

4 investors

Exo Therapeutics is a small molecule drug discovery company developing therapeutics through its ExoSight platform, which targets exosites—unique binding pockets on enzymes—to address previously undruggable diseases in oncology, inflammation, and other therapeutic areas.

4 investors

ExpressionEdits builds a computational platform, the Genetic Syntax Engine, that uses AI and intron-based transgene design to improve protein expression for therapeutic applications. The company develops an internal pipeline of therapeutic proteins and works on gene therapy partnerships.

4 investors

Extracellular is a biomanufacturing company that helps cell-based product developers in cultivated meat, plant cell culture, and bioactives accelerate discovery, overcome production challenges, and commercialize their products. The company combines scientific expertise, process innovation, and commercial insight to enable scalable, cost-effective manufacturing for the cell-based bioeconomy.

4 investors

Fabric Genomics provides an AI-based platform for next-generation sequencing (NGS) analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. The platform serves hospitals, clinical laboratories, and academic medical centers.

4 investors